No-reflow phenomenon (NRP) is an important problem in patients with ST-segment elevation myocardial infarction (STEMI) undergoing primary percutaneous coronary intervention (pPCI). Endocan is synthesized and secreted by activated vascular endothelium, and it has been shown to be related to endothelial dysfunction and inflammation. We aimed to evaluate the relationship between endocan levels and NRP. Consecutive patients (n = 137) with STEMI who had undergone coronary angiography and pPCI were enrolled into the study. The clinical characteristics of the patients were obtained and endocan levels were measured. Endocan levels were significantly higher in the NRP (+) group compared with the NRP (−) group (P < .001). In multivariate analysis, endocan (P < .001, OR = 2.39, 95% CI = 1.37-4.15) was found to be an independent predictor of NRP. An endocan value of >2.7 ng/mL has 89.6% sensitivity and 74.2% specificity for the prediction of the NRP (area under the curve: 0.832, P < .001). The present study demonstrated that the endocan level is an independent predictor of the NRP in patients with STEMI who underwent pPCI. Endocan levels may be helpful in detecting patients with a higher risk of insufficient myocardial perfusion and worse clinical outcome.
IbanezBJamesSAgewallS, et al.2017 ESC guidelines for the management of acute myocardial infarction in patients presenting with ST-segment elevation: the task force for the management of acute myocardial infarction in patients presenting with ST-segment elevation of the European society of cardiology (ESC). Eur Heart J. 2018;39:119–77.
2.
BroshDAssaliARMagerA, et al.Effect of no-reflow during primary percutaneous coronary intervention for acute myocardial infarction on six-month mortality. Am J Cardiol. 2007;99:442–5.
3.
NapodanoMRamondoATarantiniG, et al.Predictors and time-related impact of distal embolization during primary angioplasty. Eur Heart J. 2009;30:305–13.
4.
IzgiAKirmaCTanalpAC, et al.Predictors and clinical significance of angiographically detected distal embolization after primary percutaneous coronary interventions. Coron Artery Dis. 2007;18:443–9.
5.
CelikTBaltaSMikhailidisDP, et al.The relation between noreflow phenomenon and complete blood count parameters. Angiology. 2017;68:381–8.
6.
SarrazinSAdamELyonM, et al.Endocan or endothelial cell specific molecule-1 (ESM-1): a potential novel endothelial cell marker and a new target for cancer therapy. Biochim Biophys Acta Rev Cancer. 2006;1765:25–37.
7.
BechardDScherpereelAHammadH, et al.Human endothelial-cell specific molecule-1 binds directly to the integrin CD11a/CD18 (LFA-1) and blocks binding to intercellular adhesion molecule-11. J Immunol. 2001;167:3099–106.
8.
AparciMIsilakZUzOYalcinMKucukU. Endocan and endothelial dysfunction. Angiology. 2015;66:488–9.
9.
ZhangSMZuoLZhouQ, et al.Expression and distribution of endocan in human tissues. Biotech Histochem. 2012;87:172–8.
10.
KundiHBalunACicekciogluH, et al.Admission endocan level may be a useful predictor for in-hospital mortality and coronary severity index in patients with ST-segment elevation myocardial infarction. Angiology. 2017;68:46–51.
11.
ThygesenKAlpertJSJaffeASSimoonsMLChaitmanBRWhiteHD. Third universal definition of myocardial infarction. Circulation. 2012;126:2020–35.
12.
GibsonCMCannonCPMurphySAMarbleSJBarronHVBraunwaldE. Relationship of the TIMI myocardial perfusion grades, flow grades, frame count, and percutaneous coronary intervention to long term outcomes after thrombolytic administration in acute myocardial infarction. Circulation. 2002;105:1909–13.
TuranYDemirV. The relation of endocan and galectin-3 with ST-segment resolution in patients with ST-segment elevation myocardial infarction. Adv Clin Exp Med. 2020;29:453–8.
15.
LangRMBadanoLPMor-AviV, et al.Recommendations for cardiac chamber quantification by echocardiography in adults: an update from the American Society of Echocardiography and the European association of cardiovascular imaging. Eur Heart J Cardiovasc Imaging. 2015;16:233–70.
16.
IbanezBJamesSAgewallSAntunesMJBucciarelli-DucciCBuenoH. ESC Guidelines for the management of acute myocardial infarction in patients presenting with ST-segment elevation. Rev Esp Cardiol (Engl Ed). 2017;70:1082.
17.
GibsonCMde LemosJAMurphySAMarbleSJMcCabeCHCannonCP. Combination therapy with abciximab reduces angiographically evident thrombus in acute myocardial infarction: a TIMI 14 substudy. Circulation. 2001;103:2550–4.
18.
SianosGPapafaklisMISerruysPW. Angiographic thrombus burden classification in patients with ST-segment elevation myocardial infarction treated with percutaneous coronary intervention. J Invasive Cardiol. 2010;22(10 Suppl B):6B–14B.
19.
GibsonCMCannonCPDaleyWL, et al.TIMI frame count: a quantitative method of assessing coronary artery flow. Circulation. 1996;93:879–88.
20.
KurtulAAcikgozSK. Usefulness of mean platelet volume to lymphocyte ratio for predicting angiographic no-reflow and short-term prognosis after primary percutaneous coronary intervention in patients with ST-segment elevation myocardial infarction. Am J Cardiol. 2017;120:534–41.
21.
BottoNSbranaSTrianniG, et al.An increased platelet-leukocytes interaction at the culprit site of coronary artery occlusion in acute myocardial infarction: A pathogenic role for “no-reflow” phenomenon?Int J Cardiol. 2007;117:123–30.
22.
NiccoliGScaloneGLermanACreaF. Coronary microvascular obstruction in acute myocardial infarction. Eur Heart J. 2016;37:1024–33.
23.
IcliACureECureMC, et al.Endocan levels and subclinical atherosclerosis in patients with systemic lupus erythematosus. Angiology. 2016;67:749–55.
24.
BaltaSMikhailidisDPDemirkolS, et al.Endocan: A novel inflammatory indicator in cardiovascular disease?Atherosclerosis. 2015;243:339–43.
25.
LeeWKuSKKimSWBaeJS. Endocan elicits severe vascular inflammatory responses in vitro and in vivo. J Cell Physiol. 2014;229:620–30.
26.
JaipersadASLipGYSilvermanSShantsilaE. The role of monocytes in angiogenesis and atherosclerosis. J Am Coll Cardiol. 2014;63:1–11.
27.
AkpekMKayaMGLamYY, et al.Relation of neutrophil/lymphocyte ratio to coronary flow to in-hospital major adverse cardiac events in patients with ST-elevated myocardial infarction undergoing primary coronary intervention. Am J Cardiol. 2012;110:621–7.
28.
CelikTBaltaSDemirM, et al.Predictive value of admission red cell distribution width-platelet ratio for no-reflow phenomenon in acute ST segment elevation myocardial infarction undergoing primary percutaneous coronary intervention. Cardiol J. 2016;23:84–92.
29.
GuerinMLegoffWLasselTSVanTolASteinerGChapmanMJ. Proatherogenic role of elevated CE transfer from HDL to VLDL and dense LDL in type 2 diabetics. Arterioscler Thromb Vasc Biol. 2001;21:282–7.
30.
DobiasovaMFrohlichJ. The plasma parameter log (TG/HDL-C) as an atherogenic index: correlation with lipoprotein particle size and esterification rate in apo B- lipoprotein-depleted plasma (FER(HDL)). Clin Biochem. 2001;34:583–8.
31.
BaltaSCelikTOzturkC, et al.The relation between monocyte to HDL ratio and noreflow phenomenon in the patients with acute ST-segment elevation myocardial infarction. Am J Emerg Med. 2016; 34: 1542–7.
32.
KarabagYCagdasMRencuzogullariIKarakoyunSArtacIIlisD. Usefulness of the C-reactive protein/albumin ratio for predicting no-reflow in ST-elevation myocardial infarction treated with primary percutaneous coronary intervention. Eur J Clin Invest. 2018;48:e12928.
33.
SchwartzEAReavenPD. Lipolysis of triglyceride-rich lipoproteins, vascular inflammation, and atherosclerosis. Biochim Biophys Acta. 2012;1821:858–66.
34.
SüleymanoğluMRencüzoğullarıİKarabağY, et al.The relationship between atherogenic index of plasma and no-reflow in patients with acute ST-segment elevation myocardial infarction who underwent primary percutaneous coronary intervention. Int J Cardiovasc Imaging. 2020;36:789–96.
35.
QiuCRFuQSuiJ, et al.Analysis of serum endothelial cell-specific molecule 1 (Endocan) level in type 2 diabetes mellitus with acute st-segment elevation myocardial infarction and its correlation: a pilot study. Angiology. 2017;68:74–8.
